Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mechanotransduction, Cellular | 2 | 2022 | 4 | 0.900 |
Why?
|
| Zebrafish | 2 | 2022 | 5 | 0.890 |
Why?
|
| Aorta | 1 | 2024 | 20 | 0.830 |
Why?
|
| Motor Activity | 1 | 2024 | 26 | 0.830 |
Why?
|
| Animals | 20 | 2024 | 1875 | 0.720 |
Why?
|
| Endothelium, Vascular | 3 | 2024 | 30 | 0.710 |
Why?
|
| Heart Ventricles | 3 | 2015 | 15 | 0.590 |
Why?
|
| Embryo, Mammalian | 2 | 2015 | 15 | 0.480 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 4 | 0.460 |
Why?
|
| Chemokine CXCL12 | 1 | 2015 | 2 | 0.460 |
Why?
|
| Coronary Circulation | 1 | 2015 | 8 | 0.460 |
Why?
|
| Pericardium | 4 | 2019 | 16 | 0.460 |
Why?
|
| Coronary Vessels | 1 | 2015 | 44 | 0.440 |
Why?
|
| Mice | 8 | 2024 | 746 | 0.440 |
Why?
|
| Atrial Natriuretic Factor | 5 | 2010 | 21 | 0.430 |
Why?
|
| Insulin-Like Growth Factor II | 4 | 2019 | 8 | 0.430 |
Why?
|
| Myocardium | 4 | 2011 | 25 | 0.390 |
Why?
|
| Natriuretic Peptides | 2 | 2010 | 2 | 0.380 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 3 | 0.360 |
Why?
|
| Hypertension | 2 | 2010 | 147 | 0.320 |
Why?
|
| Hypertension, Renovascular | 1 | 2010 | 1 | 0.320 |
Why?
|
| Ventricular Function, Left | 1 | 2010 | 21 | 0.310 |
Why?
|
| Heart | 4 | 2019 | 25 | 0.300 |
Why?
|
| Cardiomegaly | 1 | 2007 | 4 | 0.270 |
Why?
|
| Myocytes, Cardiac | 3 | 2019 | 23 | 0.230 |
Why?
|
| Endothelial Cells | 2 | 2022 | 17 | 0.230 |
Why?
|
| Stress, Mechanical | 2 | 2022 | 9 | 0.220 |
Why?
|
| Signal Transduction | 3 | 2015 | 246 | 0.220 |
Why?
|
| Cell Proliferation | 3 | 2019 | 143 | 0.220 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2024 | 4 | 0.210 |
Why?
|
| Male | 9 | 2021 | 3671 | 0.210 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 59 | 0.200 |
Why?
|
| Rats | 7 | 2010 | 571 | 0.200 |
Why?
|
| Mice, Knockout | 3 | 2022 | 150 | 0.190 |
Why?
|
| Receptors, Notch | 1 | 2022 | 5 | 0.190 |
Why?
|
| Calcium-Binding Proteins | 1 | 2022 | 8 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2010 | 282 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 19 | 0.190 |
Why?
|
| Organogenesis | 3 | 2019 | 7 | 0.180 |
Why?
|
| Blood Coagulation | 1 | 2021 | 2 | 0.180 |
Why?
|
| Morphogenesis | 1 | 2021 | 2 | 0.180 |
Why?
|
| Tomography | 1 | 2021 | 6 | 0.180 |
Why?
|
| Electric Impedance | 1 | 2021 | 6 | 0.180 |
Why?
|
| Models, Animal | 1 | 2021 | 23 | 0.180 |
Why?
|
| Overweight | 1 | 2021 | 30 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2021 | 59 | 0.170 |
Why?
|
| Fibrin | 2 | 2021 | 5 | 0.160 |
Why?
|
| Air Pollution | 1 | 2020 | 2 | 0.160 |
Why?
|
| Air Pollutants | 1 | 2020 | 6 | 0.160 |
Why?
|
| Microbiota | 1 | 2020 | 8 | 0.160 |
Why?
|
| Receptor, Insulin | 1 | 2019 | 7 | 0.150 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2019 | 4 | 0.150 |
Why?
|
| Cells, Cultured | 3 | 2015 | 234 | 0.150 |
Why?
|
| Nephritis, Interstitial | 2 | 2006 | 6 | 0.130 |
Why?
|
| Blood Pressure | 4 | 2010 | 112 | 0.120 |
Why?
|
| Mesoderm | 1 | 2015 | 15 | 0.110 |
Why?
|
| Adipogenesis | 1 | 2015 | 13 | 0.110 |
Why?
|
| Erythropoietin | 2 | 2015 | 25 | 0.110 |
Why?
|
| PPAR gamma | 1 | 2015 | 51 | 0.110 |
Why?
|
| Female | 4 | 2021 | 4060 | 0.110 |
Why?
|
| Fructose | 2 | 2004 | 6 | 0.100 |
Why?
|
| Collagen | 2 | 2010 | 31 | 0.100 |
Why?
|
| Body Weight | 3 | 2009 | 90 | 0.090 |
Why?
|
| Liposomes | 2 | 2022 | 6 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 231 | 0.090 |
Why?
|
| Organ Size | 2 | 2009 | 31 | 0.090 |
Why?
|
| Tretinoin | 1 | 2011 | 30 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2010 | 3 | 0.080 |
Why?
|
| Desoxycorticosterone | 1 | 2010 | 5 | 0.080 |
Why?
|
| Biomechanical Phenomena | 1 | 2010 | 8 | 0.080 |
Why?
|
| Kidney Tubules | 2 | 2006 | 3 | 0.080 |
Why?
|
| Humans | 6 | 2022 | 6794 | 0.080 |
Why?
|
| Sodium | 2 | 2006 | 43 | 0.080 |
Why?
|
| Losartan | 1 | 2009 | 3 | 0.080 |
Why?
|
| NF-kappa B | 3 | 2022 | 56 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 2 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2009 | 4 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2009 | 5 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 46 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2015 | 59 | 0.070 |
Why?
|
| Chagas Disease | 2 | 2005 | 4 | 0.070 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 26 | 0.070 |
Why?
|
| Pressure | 1 | 2007 | 7 | 0.070 |
Why?
|
| DNA Primers | 1 | 2007 | 23 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 43 | 0.070 |
Why?
|
| Base Sequence | 1 | 2007 | 65 | 0.070 |
Why?
|
| Biomarkers | 3 | 2021 | 214 | 0.060 |
Why?
|
| Macrophages | 2 | 2022 | 40 | 0.060 |
Why?
|
| Inflammation | 2 | 2022 | 143 | 0.060 |
Why?
|
| Mesenteric Arteries | 1 | 2004 | 6 | 0.050 |
Why?
|
| Prostaglandins | 1 | 2004 | 7 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2004 | 4 | 0.050 |
Why?
|
| Angiotensin II | 3 | 2009 | 18 | 0.050 |
Why?
|
| Mice, Inbred ICR | 2 | 2015 | 6 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2015 | 34 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 17 | 0.050 |
Why?
|
| Arteries | 1 | 2022 | 15 | 0.050 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2002 | 1 | 0.050 |
Why?
|
| I-kappa B Kinase | 1 | 2022 | 5 | 0.050 |
Why?
|
| Shear Strength | 1 | 2022 | 1 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2022 | 11 | 0.050 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 1 | 0.040 |
Why?
|
| Microfluidics | 1 | 2021 | 1 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2002 | 31 | 0.040 |
Why?
|
| Antibodies | 1 | 2021 | 16 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 2 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2021 | 19 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 34 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 15 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2021 | 6 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 45 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 36 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 33 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 98 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 64 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 112 | 0.040 |
Why?
|
| Algorithms | 1 | 2021 | 83 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2002 | 74 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 97 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2020 | 3 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 19 | 0.040 |
Why?
|
| Middle Aged | 2 | 2021 | 2108 | 0.040 |
Why?
|
| Risk Factors | 1 | 2021 | 767 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 118 | 0.040 |
Why?
|
| Aged | 1 | 2021 | 1539 | 0.030 |
Why?
|
| Adult | 1 | 2021 | 2113 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2015 | 9 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2015 | 1 | 0.030 |
Why?
|
| Receptors, Erythropoietin | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 7 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 12 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 28 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 50 | 0.030 |
Why?
|
| Gestational Age | 1 | 2015 | 58 | 0.030 |
Why?
|
| Oxygen | 1 | 2015 | 44 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 124 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 91 | 0.030 |
Why?
|
| Placenta | 1 | 2015 | 58 | 0.030 |
Why?
|
| Trypanosoma cruzi | 2 | 2005 | 4 | 0.030 |
Why?
|
| Prognosis | 2 | 2005 | 220 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 599 | 0.020 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2011 | 1 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 26 | 0.020 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2011 | 1 | 0.020 |
Why?
|
| Keratolytic Agents | 1 | 2011 | 1 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 4 | 0.020 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2011 | 2 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 5 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 13 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 90 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 157 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2009 | 5 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2009 | 5 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 48 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2009 | 17 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 95 | 0.020 |
Why?
|
| Kidney Medulla | 1 | 2006 | 1 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2006 | 8 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2006 | 9 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cell Respiration | 1 | 2006 | 2 | 0.020 |
Why?
|
| Biological Transport | 1 | 2006 | 22 | 0.020 |
Why?
|
| Hypoxia | 1 | 2006 | 37 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 17 | 0.020 |
Why?
|
| Actins | 1 | 2006 | 28 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 20 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 55 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 155 | 0.020 |
Why?
|
| Myocarditis | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2005 | 4 | 0.010 |
Why?
|
| Enzyme Activators | 1 | 2002 | 1 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2002 | 8 | 0.010 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2002 | 3 | 0.010 |
Why?
|
| Naphthalenes | 1 | 2002 | 5 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 13 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 53 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 39 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 31 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2002 | 47 | 0.010 |
Why?
|
| Insulin | 1 | 2002 | 146 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 165 | 0.010 |
Why?
|